» Articles » PMID: 27426304

The Evolution of P2X7 Antagonists with a Focus on CNS Indications

Overview
Specialty Biochemistry
Date 2016 Jul 19
PMID 27426304
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

The P2X7 receptor is an ATP-gated nonselective cation channel that has been linked to a number of inflammatory diseases. Activation of the P2X7 receptor by elevated levels of ATP results in the release of proinflammatory cytokines and elevated levels of these cytokines has been associated with a variety of disease states. A number of research groups in both industry and academia have explored the identification of P2X7R antagonists as therapeutic agents. Much of this early effort focused on the treatment of diseases related to peripheral inflammation and resulted in several clinical candidates, none of which were advanced to market. The emerging role of the P2X7 receptor in neuroinflammation and related diseases has resulted in a shift in medicinal chemistry efforts toward the development of centrally penetrant antagonists. This review will highlight the biology supporting the role of P2X7 in diseases related to neuroinflammation and review the recent medicinal chemistry efforts to identify centrally penetrant antagonists.

Citing Articles

A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists.

Soni S, Lukhey M, Thawkar B, Chintamaneni M, Kaur G, Joshi H Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4643-4656.

PMID: 38349395 DOI: 10.1007/s00210-024-02994-z.


Integrating UHPLC-MS/MS quantitative analysis and exogenous purine supplementation to elucidate the antidepressant mechanism of Chaigui granules by regulating purine metabolism.

Chen J, Li T, Huang D, Gong W, Tian J, Gao X J Pharm Anal. 2024; 13(12):1562-1576.

PMID: 38223448 PMC: 10785246. DOI: 10.1016/j.jpha.2023.08.008.


Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.

Recourt K, de Boer P, Van Der Ark P, Benes H, van Gerven J, Ceusters M Transl Psychiatry. 2023; 13(1):266.

PMID: 37482560 PMC: 10363543. DOI: 10.1038/s41398-023-02557-5.


Leveraging the ATP-P2X7 receptor signalling axis to alleviate traumatic CNS damage and related complications.

Yin Y, Wei L, Caseley E, Lopez-Charcas O, Wei Y, Li D Med Res Rev. 2023; 43(5):1346-1373.

PMID: 36924449 PMC: 10947395. DOI: 10.1002/med.21952.


Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?.

Schmidt S, Isaak A, Junker A Int J Mol Sci. 2023; 24(2).

PMID: 36674884 PMC: 9861945. DOI: 10.3390/ijms24021374.